CASI Closes Patient Enrollment in Study of ENMD-2076 for Triple-Negative Breast Cancer
News
CASI Pharmaceuticals has closed enrollment in its Phase 2 clinical trial of ENMD-2076 for previously treated locally advanced or metastatic triple-negative breast cancer (TNBC). The 41 American patients it has enrolled so ... Read more